Immune cell markers in adults with bipolar disorder compared with healthy people
Compares markers on CD8+ T cells in blood of people with and without bipolar disorder.
Plain-language title generated from the registry record
Registry title: Chemokine Receptors on CD8+ T Cells in Patients With Bipolar Disorder
Key facts
- Where
- Catania, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 35 years old?
Source: NCT07785167, who can take part
Where in Italy
- Psychiatry Unit, Policlinico "G.Rodolico" Hospital, Via Santa Sofia 78Catania, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Catania
- Trial code
- NCT07785167
- Record updated
- 25 August 2026
- Original description
This observational study investigates the expression profile of chemokine receptors and adhesion molecules in CD8+ T lymphocytes from individuals with Bipolar Disorder compared with healthy controls. The study focuses on CCR5 and CXCR3, which are involved in CD8+ T-cell migration toward the central nervous system, as well as the adhesion-related molecules PSGL-1, VLA-4, and LFA-1. Participants with Bipolar I or Bipolar II Disorder will be drug-naive or drug-free for at least 6 months and will be compared with healthy controls. Differences in molecular expression will also be explored according to the current mood episode, including depressive and manic/hypomanic phases. Gene expression will be assessed by real-time PCR in purified CD8+ T lymphocytes obtained from peripheral blood samples.Read full original descriptionShow less
Characterization of Chemokine Receptor Expression in CD8+ T Lymphocytes in Bipolar Disorder
This observational study investigates the expression profile of chemokine receptors and adhesion molecules in CD8+ T lymphocytes from individuals with Bipolar Disorder compared with healthy controls. The study focuses on CCR5 and CXCR3, which are involved in CD8+ T-cell migration toward the central nervous system, as well as the adhesion-related molecules PSGL-1, VLA-4, and LFA-1. Participants with Bipolar I or Bipolar II Disorder will be drug-naive or drug-free for at least 6 months and will be compared with healthy controls. Differences in molecular expression will also be explored according to the current mood episode, including depressive and manic/hypomanic phases. Gene expression will be assessed by real-time PCR in purified CD8+ T lymphocytes obtained from peripheral blood samples.
Inclusion: Participants with Bipolar Disorder:; Age 25 to 35 years; Male or female; female participants must be in the mid-luteal phase of the menstrual cycle; Clinical presentation consistent with a diagnosis of Bipolar I Disorder or Bipolar II Disorder; First diagnosis of Bipolar Disorder with no previous psychopharmacological treatment (drug-naive), or absence of psychopharmacological treatment for at least 6 months (drug-free); Ability and willingness to provide written informed consent; Healthy Controls Group:; Age 25 to 35 years; Male or female; female participants must be in the mid-luteal phase of the menstrual cycle; No current treatment with psychotropic medications; No clinical or symptomatic evidence supporting a diagnosis of Bipolar I Disorder or Bipolar II Disorder; Hamilton Depression Rating Scale (HAM-D) score <8; Mania Rating Scale (MRS) score <11; No major stressful life events during the previous 6 months, such as bereavement, traumatic events, or divorce; Ability and willingness to provide written informed consent.
Exclusion: Current treatment with corticosteroids, immunosuppressive agents, antibiotics, or hormone replacement therapy; Current psychopharmacological treatment or psychopharmacological treatment discontinued less than 6 months before enrollment; Relevant current medical comorbidities, including autoimmune diseases or other clinically significant internal medicine conditions; Relevant psychiatric comorbidities.